Mario Sznol

Q: What Schools Are Affiliated With Mario Sznol

Mario Sznol is affiliated with the following schools: Yale University, Ohio State University, Vanderbilt University, University of Toronto, University of Manchester, New York University

Mario Sznol's AcademicInfluence.com Rankings

Mario Sznol

Philosophy

#7430

World Rank

#10645

Historical Rank

Logic

#4479

World Rank

#5781

Historical Rank

philosophy Degrees

Mario Sznol

Biology

#10094

World Rank

#13386

Historical Rank

Immunology

#625

World Rank

#645

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Mario Sznol Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Mario Sznol's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (2012) (10640)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (2015) (3858)
Nivolumab plus ipilimumab in advanced melanoma. (2013) (3808)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. (2015) (2259)
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. (2014) (2043)
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. (1999) (1879)
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. (1995) (1249)
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma (2012) (1047)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. (2015) (1015)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. (2012) (963)
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. (2017) (806)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. (2016) (781)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (750)
Programmed death ligand-1 expression in non-small cell lung cancer (2014) (707)
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. (2002) (564)
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. (2000) (542)
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer (2013) (503)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma (2016) (500)
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. (2016) (495)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3 (2019) (445)
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. (2015) (400)
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. (2017) (367)
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo (2015) (355)
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. (2017) (347)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab (2011) (323)
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors (2018) (320)
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (2019) (316)
Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas (2015) (309)
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. (2012) (300)
Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205 (2014) (296)
PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells (2010) (295)
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. (2010) (282)
Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy (2015) (281)
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients (2017) (274)
A clinical development paradigm for cancer vaccines and related biologics. (2007) (274)
Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients (2003) (268)
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 (2010) (264)
Early B cell changes predict autoimmunity following combination immune checkpoint blockade (2018) (255)
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody (2016) (243)
First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. (2017) (233)
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. (2017) (213)
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (2016) (208)
Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) (2008) (203)
Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. (1990) (203)
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. (2017) (201)
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. (1999) (194)
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites (2015) (184)
Genome-wide screen of promoter methylation identifies novel markers in melanoma. (2009) (183)
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. (2014) (179)
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. (2017) (172)
Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. (2019) (169)
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. (1993) (168)
Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. (1996) (158)
Use of preferentially replicating bacteria for the treatment of cancer. (2000) (154)
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. (1992) (147)
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors (2017) (145)
Immunotherapy of Melanoma: Facts and Hopes (2019) (139)
Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy (2011) (135)
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. (2017) (132)
The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin (1993) (131)
Bullous disorders associated with anti–PD‐1 and anti–PD‐L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy (2018) (129)
Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation (2005) (125)
Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. (2014) (125)
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study. (2019) (123)
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). (2020) (122)
Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. (2004) (120)
Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response (2013) (117)
A phase 2 trial of dasatinib in advanced melanoma (2011) (109)
Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). (2013) (109)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. (2019) (108)
A Melanoma Brain Metastasis with a Donor-Patient Hybrid Genome following Bone Marrow Transplantation: First Evidence for Fusion in Human Cancer (2013) (104)
A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. (1991) (103)
Exome sequencing identifies recurrent somatic RAC 1 mutations in melanoma (2016) (103)
Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. (2016) (103)
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors (2017) (101)
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. (2003) (101)
Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. (2015) (100)
High-dose aldesleukin in renal cell carcinoma: long-term survival update. (1997) (99)
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2018) (98)
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy (2020) (97)
The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization (2007) (94)
MicroRNA signatures differentiate melanoma subtypes (2011) (94)
Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. (2010) (94)
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. (2003) (94)
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. (2008) (94)
Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis. (2014) (89)
Plasma Markers for Identifying Patients with Metastatic Melanoma (2011) (89)
White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy (2011) (88)
Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer (2005) (87)
Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial (2016) (86)
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. (1990) (85)
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer (2004) (84)
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce (2020) (83)
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. (1990) (82)
Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. (2019) (81)
Biology of advanced uveal melanoma and next steps for clinical therapeutics (2014) (79)
LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY (2014) (76)
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer (2019) (75)
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. (2014) (72)
A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). (2017) (71)
Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. (2013) (70)
Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. (2014) (69)
Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis. (2015) (69)
Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma (2020) (68)
Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up. (2013) (67)
Ipilimumab-induced perforating colitis. (2013) (67)
Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications (2009) (67)
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. (2007) (65)
IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). (2017) (63)
Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. (2014) (63)
Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. (1994) (62)
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 (2020) (60)
T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma (2022) (60)
Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. (1998) (59)
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements (2021) (59)
Classification of renal cell carcinoma based on expression of VEGF and VEGF receptors in both tumor cells and endothelial cells (2008) (53)
A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia (2004) (53)
Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). (2015) (52)
Toxicity and Activity of a Twice Daily High-dose Bolus Interleukin 2 Regimen in Patients With Metastatic Melanoma and Metastatic Renal Cell Cancer (2008) (52)
A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma (2017) (51)
Human gene marker/therapy clinical protocols. (1999) (51)
Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. (2016) (50)
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. (2006) (49)
NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT. (2018) (48)
Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a. (1991) (48)
Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. (1989) (47)
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma (2019) (47)
Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab. (2013) (45)
Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. (2019) (45)
Melanoma: A model for testing new agents in combination therapies (2010) (44)
Phase I and immunomodulatory study of a muramyl peptide, muramyl tripeptide phosphatidylethanolamine. (1990) (42)
A Variant in a MicroRNA Complementary Site in the 3′UTR of the KIT Oncogene Increases Risk of Acral Melanoma (2010) (41)
Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition. (2019) (40)
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma (2019) (39)
Key issues in the management of gastrointestinal immune-related adverse events associated with ipilimumab administration (2013) (39)
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects. (1993) (39)
Phase I Study of Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, Combined with Cytarabine in Patients with Refractory Leukemia (2005) (38)
Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. (2010) (38)
Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. (2015) (38)
Melanoma brain metastases: is it time to reassess the bias? (2011) (37)
Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. (1992) (37)
Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation (2016) (36)
Dose-related immunologic effects of levamisole in patients with cancer. (1993) (36)
Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies (2016) (36)
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma (2020) (36)
Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma (2006) (35)
Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series. (2019) (35)
Blockade of the B7-H1/PD-1 Pathway as a Basis for Combination Anticancer Therapy (2014) (35)
C-Raf Is Associated with Disease Progression and Cell Proliferation in a Subset of Melanomas (2009) (35)
A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies. (2011) (34)
A Phase I Trial of B7-Transfected or Parental Lethally Irradiated Allogeneic Melanoma Cell Lines to Induce Cell-Mediated Immunity Against Tumor-Associated Antigen Presented by HLA-A2 or HLA-A1 in Patients with Stage IV Melanoma. National Institutes of Health, Bethesda, Maryland (1995) (34)
Case Report: response to ipilimumab in a patient with HIV with metastatic melanoma. (2011) (33)
Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). (2013) (33)
Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. (1997) (33)
Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma (2016) (33)
Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors (1993) (32)
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study (2020) (32)
A Phase II Clinical Trial of Interleukin‐2 and Lymphokine‐Activated Killer Cells in Advanced Colorectal Carcinoma (1994) (32)
Frequent dosing and GPNMB expression with CDX-011 (CR011-vcMMAE), an antibody-drug conjugate (ADC), in patients with advanced melanoma. (2010) (31)
Genitourinary tumors, non-prostate (2012) (31)
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma (2021) (30)
809OIMMUNE CORRELATES AND LONG TERM FOLLOW UP OF A PHASE IA STUDY OF MPDL3280A, AN ENGINEERED PD-L1 ANTIBODY, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (30)
A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b. (1990) (29)
BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). (2013) (29)
Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. (1996) (29)
Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. (2015) (29)
Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma. (1989) (26)
Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma (2017) (26)
Use of prophylactic antibiotics for prevention of intravascular catheter-related infections in interleukin-2-treated patients. (1989) (25)
Phase II Trial of Interleukin 1α and Indomethacin in Treatment of Metastatic Melanoma (1996) (25)
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1 (2021) (25)
Chitinase-like proteins in lung injury, repair, and metastasis. (2012) (23)
Betting on immunotherapy for melanoma (2009) (23)
Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (23)
Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab (2014) (23)
Molecular Markers of Response to Treatment for Melanoma (2011) (22)
Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study. (1992) (22)
High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma. (1995) (22)
Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphoma. (1991) (22)
Antigen-specific agents in development. (1997) (22)
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12. (2005) (21)
Therapeutic combinations of immune-modulating antibodies in melanoma and beyond. (2015) (21)
Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL). (2012) (21)
Influence of interleukin-2 regimens on circulating populations of lymphocytes after adoptive transfer of anti-CD3-stimulated T cells: results from a phase I trial in cancer patients. (1996) (21)
A phase II trial of dasatinib in advanced melanoma. (2009) (20)
1085OSURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL). (2014) (20)
Immune monitoring after NKTR-214 plus nivolumab (PIVOT-02) in previously untreated patients with metastatic stage IV melanoma (2019) (20)
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (20)
Effect of a novel IL-2 cytokine immune agonist (NKTR-214) on proliferating CD8+T cells and PD-1 expression on immune cells in the tumor microenvironment in patients with prior checkpoint therapy. (2017) (19)
Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis (2018) (19)
Baseline tumor-immune signatures associated with response to bempegaldesleukin (NKTR-214) and nivolumab. (2019) (19)
Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, DUR) + tremelimumab (TRE) in patients with advanced solid tumors. (2017) (19)
A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma. (1995) (19)
Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype? (2010) (19)
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma. (2001) (18)
Abrogation of the hematological and biological activities of the interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. (1999) (18)
Cancer Immunotherapy: Past Progress and Future Directions. (2015) (18)
A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer (2005) (18)
A phase I randomized study of subcutaneous adjuvant IL-2 in combination with an autologous tumor vaccine in patients with advanced renal cell carcinoma. (1996) (18)
Interleukin-2 in therapy of hematologic malignancies [editorial; comment] (1994) (18)
Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors. (2015) (18)
Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7 th2010" (2011) (18)
Immune Modulation Therapy and Imaging: Workshop Report (2017) (17)
A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate (ADC) targeting glycoprotein NMB (GPNMB) in patients (pts) with advanced melanoma. (2016) (17)
Phase Ib study of PF-05082566 in combination with pembrolizumab in patients with advanced solid tumors. (2016) (17)
Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC). (2012) (16)
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. (2020) (16)
Clinical applications of IL-2. (1994) (16)
Hepatic toxicity of drugs used for hematologic neoplasia. (1987) (15)
Diminished but not dead: chemotherapy for the treatment of NSCLC. (2016) (15)
Release the hounds! Activating the T-cell response to cancer. (2015) (15)
Interleukin-2 in therapy of hematologic malignancies. (1994) (15)
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC (2021) (15)
A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with prosorba columns for treating metastatic breast cancer (1995) (14)
A phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma (2008) (13)
Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results. (2012) (13)
A novel anti-melanoma SRC-family kinase inhibitor (2019) (13)
First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study. (2017) (13)
Melanoma and other skin tumors (2012) (13)
Advances in the treatment of metastatic melanoma: new immunomodulatory agents. (2012) (13)
In vitro studies of dasatinib, its targets and predictors of sensitivity (2011) (13)
Melanoma and immunotherapy bridge 2015 (2016) (13)
Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (2012) (13)
A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence (2015) (12)
VEGF, VEGFR1, and VEGFR2 expression in melanoma (2007) (12)
A phase 1 multicenter open-label dose-escalation study of BMS-936561 (MDX-1203) in clear cell renal cell carcinoma (ccRCC) and B-cell non Hodgkin lymphoma (B-NHL). (2014) (11)
Chemotherapy drug interactions with biological agents. (1993) (11)
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218) (2020) (11)
Resistance mechanisms to checkpoint inhibitors. (2021) (11)
Adrenal insufficiency and interleukin-2 therapy. (1989) (11)
Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis. (2013) (10)
A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. (2017) (10)
Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant (2015) (10)
Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma. (1996) (9)
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer (2017) (9)
Pre-treatment patient selection for nivolumab benefit based on serum mass spectra (2015) (9)
Pharmacokinetics (PK) of CR011-vcMMAE, an antibody-drug conjugate (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma. (2016) (8)
5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancer. (1990) (8)
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors (2022) (8)
Evaluation of clinical endpoints as surrogates for overall survival in patients treated with immunotherapies. (2017) (8)
Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). (2013) (8)
Phase I Trial of Triapine–Cisplatin–Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers (2017) (8)
Abstract CT106: A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma (2015) (8)
A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401. (1995) (8)
A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2. (1995) (8)
Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. (2021) (8)
Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM). (2017) (8)
Revisiting Anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy. (2020) (8)
Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis (2022) (8)
Advances in the systemic treatment of metastatic melanoma. (2013) (8)
Biologic therapies for low-grade lymphomas. (1993) (8)
Outcomes of Stereotactic Radiosurgery and Immunotherapy in Renal Cell Carcinoma Patients With Brain Metastases (2021) (8)
1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL. (2014) (7)
Identification of adenosine pathway genes associated with response to therapy with the adenosine receptor antagonist CPI-444. (2018) (7)
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function (2022) (7)
Overall survival (OS) analysis from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL). (2017) (7)
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study (2022) (7)
Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review (2022) (6)
Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers (2012) (6)
Anti-PD-1 (BMS-936558/MDX-1106/ONO-4538) in Patients With Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers (2012) (6)
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors (2022) (6)
Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study. (1992) (6)
Prolonged , Continuous Treatment of Hairy Cell Leukemia Patients With Recombinant Interferon-da (2003) (6)
Peripheral blood and tumor biomarkers in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (2013) (6)
Clinical trials referral resource. NCI-sponsored trials of interleukin-6 (IL-6). (1993) (6)
Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (2012) (5)
1088PDLONG-TERM SURVIVAL OF IPILIMUMAB-NAïVE PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN A PHASE 1 TRIAL. (2014) (5)
785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL) (2022) (5)
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study (2020) (5)
1212TiPPIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies (2017) (4)
A phase I and pharmacokinetic study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III /IV melanoma (2007) (4)
Relationship between clinical efficacy and AEs of IMCgp100, a novel bispecific TCR–anti-CD3, in patients with advanced melanoma. (2019) (4)
A Phase II trial of pembrolizumab for patients with melanoma or non-small cell lung cancer and untreated brain metastases (2017) (4)
Clinical Trials Referral Resource. Trials using tumor vaccines. (1997) (4)
Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006. (2021) (4)
P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies (2017) (4)
Combination immunotherapy: Where do we go from here? (2015) (4)
Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Previously Treated, Metastatic Renal Cell Carcinoma (MRCC) (2012) (4)
TUMOR ANTIGENS AS TARGETS FOR ANTICANCER DRUG DEVELOPMENT (2002) (4)
Analysis of pre-treatment O-6-alkylguanine transferase (AGT) levels in patients (pts) with hematologic malignancies receiving VNP40101M (101M). (2005) (4)
Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma (2022) (3)
Effect of NKTR-214 on the number and activity of CD8+ tumor infiltrating lymphocytes in patients with advanced renal cell carcinoma. (2017) (3)
Phase Ib, open-label, dose-escalation study of M9241 (NHS-IL12) plus avelumab in patients (pts) with advanced solid tumours (2019) (3)
Pharmacodynamic effect of IMCgp100 (TCR–CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma. (2019) (3)
CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL). (2019) (3)
Safety profile of nivolumab (NIVO) and ipilimumab (IPI) combination therapy in patients (pts) with advanced melanoma (MEL) (2016) (3)
Adoptive cellular therapy. (1992) (3)
Antibodies and Recombinant Cytokines (2005) (3)
Tumour therapy using Salmonella (2000) (3)
Expanded use trials-are there better approaches to minimize adverse consequences to the clinical trials program? (2014) (2)
Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma. (2019) (2)
Introducing a New Series: Immunotherapy Facts and Hopes (2018) (2)
A phase I, open-label, multicenter, single-dose escalation and multi-dose study of a monoclonal antibody targeting CEACAM1 in subjects with selected advanced or recurrent malignancies. (2020) (2)
Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts (2020) (2)
Challenges in Conducting Clinical Research on Patients With Advanced Melanoma. (2017) (2)
Abstract CT329: A Phase I study of IMCgp100: durable responses with a novel first-in-class immunotherapy for advanced melanoma (2014) (2)
Immune monitoring of cancer vaccines. Report on a workshop held at the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. (1996) (2)
Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL). (2016) (2)
A phase I study of sunitinib in combination with sirolimus in adults with advanced refractory malignancies. (2009) (2)
Cytokine release syndrome (CRS) following treatment with tebentafusp, a novel bispecific TCR-anti-CD3 directed against gp100, in patients with advanced melanoma (2019) (2)
A Phase I trial of the sulfonylhydrazine alkylator, VNP40101M (101M), administered weekly in patients (pts) with metastatic cancer. (2004) (1)
Clinical significance of programmed death ligand-1 expression in non-small cell lung cancer (NSCLC). (2013) (1)
Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab (2015) (1)
Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006 (2017) (1)
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors (2021) (1)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (1)
Combination Strategies PD-1/PD-L1 Antagonists. (2018) (1)
T-cell adoptive immunotherapy: moving ahead by going in a circle. (2000) (1)
Revisiting ribonucleotide reductase as a target to enhance radiation and chemotherapy anti-tumor activity. (2003) (1)
Dose escalation of davoceticept, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1). (2022) (1)
Dhodapkar NY-ESO-1 to the Dendritic Cell Receptor DEC-205 Induction of Antigen-Specific Immunity with a Vaccine Targeting (2014) (1)
Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications (2023) (1)
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02. (2022) (1)
Integrative molecular and clinical profiling of acral melanoma identifies LZTR1 as a key tumor promoter and therapeutic target (2021) (1)
Abstract 1477: Tumor cell-leukocyte fusion in human cancer: A melanoma brain metastasis with a donor-patient hybrid genome following allogeneic BMT (2011) (1)
Clinical trials referral resource. Tumor Vaccine Trials. (1998) (1)
Phase II Trial of High-Dose Interleukin-2 and Lymphokine-Activated Killer Cells in Hodgkin's Disease and Non-Hodgkin's Lymphom (1991) (1)
Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual melanoma metastases. (2017) (1)
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC) (2022) (1)
RBTT-07. A PHASE 2 TRIAL OF PEMBROLIZUMAB AND BEVACIZUMAB IN MELANOMA BRAIN MET PATIENTS (2019) (1)
Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy (2019) (1)
389 Phase II of CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy (2021) (1)
Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab (2014) (1)
Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma. (2020) (1)
TUMOR VACCINE TRIALS (1998) (1)
Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma. (2023) (1)
772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01) (2022) (1)
Changes in serum IL8 levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small cell lung cancer patients (2016) (1)
Abstract CT041: Monotherapy dose escalation of davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies (NEON-1) (2022) (1)
Abstract PR05: Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo (2015) (0)
Adoptive cellular therapy. (1991) (0)
Phase I Study of Triapine® and Cytarabine (ara-C) in Patients with Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndrome (MDS). (2005) (0)
3:30 PM Abstract No. 345 Safety and feasibility of immuno-cryotherapy (2018) (0)
Parkinson comment ] Interleukin-2 in therapy of hematologic malignancies (2002) (0)
TIL in Melanoma—Similar Approaches, Different Results, Unanswered Questions (2021) (0)
Coupled fibromodulin and SOX2 signaling as a critical regulator of distant metastasis initiation in melanoma (2022) (0)
Developing enabling technologies for the success of cancer immunotherapy. (2004) (0)
A 71-year-old woman with decreased vision, nyctalopia, and peripheral vision loss. (2016) (0)
An exploratory study to investigate the immunomodulatory activity of BMS-936558 in patients with metastatic clear-cell renal cell carcinoma. (2012) (0)
Phase I and Pharmacokinetic Study of Triapine , a Potent Ribonucleotide Reductase Inhibitor , Administered Daily for Five Days in Patients with Advanced Solid Tumors 1 (2003) (0)
Selective accumulation of attenuated Salmonella in solid tumors - a new anti-cancer vector (2001) (0)
ISY9-3Proteomic and T cell biomarkers identify sensitivity and resistance to immunotherapy in cancer patients (2017) (0)
KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements (2021) (0)
Safety and feasibility of immuno-cryotherapy. (2018) (0)
Abstract 6670: Association between circulating CD4 memory T cell levels and severe immune-related adverse events in melanoma patients treated with immune checkpoint blockade (2023) (0)
Melanoma and immunotherapy bridge 2015 (2016) (0)
a Peptide Vaccine Patients with Metastatic Melanoma Receiving Generation of Antitumor Reactivity in Impact of Cytokine Administration on the (1999) (0)
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy (2020) (0)
Outcomes of Melanoma Brain Metastasis Management with Gamma Knife Radiosurgery +/- Ipilimumab (2011) (0)
Relative roles of targeted therapies and immunotherapies in melanoma. (2012) (0)
Adoptive Immunotherapy (2003) (0)
Adoptive immunotherapy. (2020) (0)
Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives—a meeting report (2020) (0)
Safety and Efficacy of Pembrolizumab in US Patients Enrolled in KEYNOTE-030, an Expanded Access Program (2015) (0)
Tissue resident memory T cells create genetically distinct immune microenvironments within melanoma metastasis (2015) (0)
Validation of the prognostic utility of the gene expression profiling test in patients with uveal melanoma. (2023) (0)
Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer (2014) (0)
1085O SURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIALOF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCEDMELANOMA (MEL) (2014) (0)
Author Correction: Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis (2022) (0)
Clinical predictors of longer survival in patients with BRAFV600-mutated metastatic melanoma receiving immunotherapy prior to BRAF/MEK inhibition in the metastatic setting. (2022) (0)
Phase I S tudy o f t he I ntravenous A dministration o f Attenuated Salmonella t yphimurium to P atients W ith Metastatic M elanoma (2002) (0)
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R af Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors (2019) (0)
Immunotherapy for cancer: focusing on developing treatments rather than drugs. (2001) (0)
Ablation of Histone Demethylase KDM5B in Melanoma Augments Anti-Tumor Immunity through Upregulation of Retroelements (2020) (0)
9306 Phase II multi-institution trial of ipilimumab for patients with melanoma and brain metastasis (2009) (0)
21 Plasma-based proteomic profiling as a tool for predicting response to immunotherapy in melanoma patients (2020) (0)
Human gene marker/therapy clinical protocols. (2000) (0)
Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors (2019) (0)
Anti-CD 3 Monoclonal Antibody Treatment of Patients with CD 3-Negative Tumors : A Phase IA / B Study 1 (2006) (0)
Abstract 3287: A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better (2023) (0)
Abstract 1179: Rational combinations with the dual RAF/MEK inhibitor VS-6766 for treatment of cutaneous melanoma harboring BRAF, NRAS, NF1 or CRAF mutations (2022) (0)
IS5-4CHECKPOINT INHIBITORS AS A FOUNDATION FOR ANTI-CANCER IMMUNE THERAPY (2014) (0)
Immunotherapy earns its spot in the ranks of cancer therapy (2012) (0)
Relationship between clinical efficacy and AEs of tebentafusp, a novel bispecific TCR-anti-CD3, in patients with advanced melanoma (2020) (0)
Mario Sznol, MD on the Future of Addressing Drug Resistance (2019) (0)
Abstract 1306: Biomarker results from a clinical trial of nivolumab in patients (pts) with metastatic renal cell carcinoma (mRCC) (CA209-009): Gene expression, serum profiling for immune markers, and multiplex tissue immunohistochemistry (IHC) (2015) (0)
What is the first-line treatment of choice for metastatic BRAF-mutant melanoma? (2012) (0)
Clinical trials referral resource. Tumor vaccine clinical trials. (1995) (0)
Expression and prognostic value of TRAIL receptors R1 and R2 in early stage breast cancer (2005) (0)
The Phoenix Rises: The Rebirth of Cancer Immunotherapy. (2017) (0)
What Tx is your first choice for metastatic BRAF+ melanoma? (2011) (0)
Melanoma patients with durable responses to IL-2 treatment: role of surgical salvage for persistent or recurrent disease (1997) (0)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023) (0)
Evaluating the Medical Management of Locally Advanced and Metastatic Basal Cell Carcinoma: A Single Institutional Retrospective Analysis Investigating Efficacy, Safety, and Tolerability (2023) (0)
Pharmacodynamic effect of tebentafusp (TCR-CD3 bispecific) on peripheral cytokines and association with overall survival in patients with advanced melanoma (2020) (0)
Phase I study of VNP40101M (101M) and AraC in patients (pts) with refractory leukemia (2004) (0)
Abstracts from the 4th ImmunoTherapy of Cancer Conference (2017) (0)
A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma. (2020) (0)
Abstract CT034: GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors (2023) (0)
Reversing Resistance to Checkpoint Inhibitors and Targeted Therapy in Metastatic Melanoma. (2020) (0)
Phase I study of VNP40101M (101M) and AraC in patients (pts) with refractory leukemia. (2004) (0)
High-Dose R ecombinant I nterleukin 2 T herapy f or P atients With M etastatic M elanoma: A nalysis o f 2 70 P atients Treated B etween 1 985 a nd 1 993 (1999) (0)
Treatment of Melanoma with Agonist Immune Costimulatory Agents (2012) (0)
CommentaryA model for testing new agents in combination therapies (2010) (0)
Immunotherapy Bridge 2020 and Melanoma Bridge 2020: meeting abstracts (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Mario Sznol?

Mario Sznol is affiliated with the following schools:

Mario Sznol's Academic­Influence.com Rankings

Why Is Mario Sznol Influential?

Mario Sznol's Published Works

Published Works

What Schools Are Affiliated With Mario Sznol?

Mario Sznol's AcademicInfluence.com Rankings